{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Cabergoline", "Design-Expert", "PEG", "Suppository", "Vomiting"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "38028218", "DateRevised": {"Year": "2023", "Month": "12", "Day": "01"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "11", "Day": "04"}], "Language": ["eng"], "ELocationID": ["101849", "10.1016/j.jsps.2023.101849"], "Journal": {"ISSN": "1319-0164", "JournalIssue": {"Volume": "31", "Issue": "12", "PubDate": {"Year": "2023", "Month": "Dec"}}, "Title": "Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society", "ISOAbbreviation": "Saudi Pharm J"}, "ArticleTitle": "Preparation and characterization of vaginal suppository of semisynthetic derivatives of ergot alkaloids cabergoline.", "Pagination": {"StartPage": "101849", "MedlinePgn": "101849"}, "Abstract": {"AbstractText": ["There is evidence that vaginal cabergoline can help to prevent ovarian hyperstimulation syndrome. Therefore, the vaginal suppository may be a good choice because it can be administered directly into the vagina and has no adverse effects on the stomach. In this regard we developed a cabergoline suppository as an alternative to cabergoline tablets. Design-Expert was used to determine the most suitable concentrations of PEG 6000/400, and Tween 80 to obtain a stable suppository. Specific ratios of PEG6000/400 and Tween 80 were entered as factors, and release, melting time, and hardness were evaluated as responses. In addition, the final formulation was evaluated for weight changes, pH, drug content, degradation time, deformation time, <i>in vitro</i> drug release, DSC analysis, infrared spectroscopy, and stability properties.", "The suppositories were all smooth and white. They all had a weight that averaged less than 5\u00a0%. The formulations showed a pH between 6 and 6.5. The active ingredient content ranged between 79.666\u00a0\u00b1\u00a08.54\u00a0% and 99.67\u00a0\u00b1\u00a06.55\u00a0%. Suppository stiffness was between 2.74\u00a0\u00b1\u00a00.04 and 4.20\u00a0\u00b1\u00a00.03. The decomposition time of the suppositories varied between 11.25\u00a0\u00b1\u00a00.15 to 20.19\u00a0\u00b1\u00a00.08\u00a0min. The deformation time was between 26.11\u00a0\u00b1\u00a00.06 to 38.59\u00a0\u00b1\u00a00.47\u00a0min. Cabergoline content was released over 45\u00a0min from formulations of F10 (\u223c46\u00a0%), F2 (\u223c64\u00a0%), F6 (\u223c69\u00a0%), F4 (\u223c79\u00a0%), F1 (\u223c88\u00a0%), and F7 (\u223c93\u00a0%). However, other formulations released more than 95\u00a0% within 45\u00a0min.", "All variables except melting time significantly affected our responses. <i>In vitro</i> studies have indicated that the optimized cabergoline formula could be an excellent alternative to cabergoline oral formulations."], "CopyrightInformation": "\u00a9 2023 The Author(s)."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran."}, {"Identifier": [], "Affiliation": "Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Rahmanian-Devin", "ForeName": "Pouria", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Fadaei", "ForeName": "Mohammad Reza", "Initials": "MR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Mashreghi", "ForeName": "Mohammad", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran."}, {"Identifier": [], "Affiliation": "Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran."}, {"Identifier": [], "Affiliation": "Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Askari", "ForeName": "Vahid Reza", "Initials": "VR"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Saudi Arabia", "MedlineTA": "Saudi Pharm J", "NlmUniqueID": "9705695", "ISSNLinking": "1319-0164"}, "CoiStatement": "The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Abd Ellah N.H., et al. Vaginal suppositories of cumin seeds essential oil for treatment of vaginal candidiasis: Formulation, in vitro, in vivo, and clinical evaluation. Eur. J. Pharm. Sci. 2021;157", "ArticleIdList": ["33086117"]}, {"Citation": "Aboulghar M. Seminars in Reproductive Medicine. \u00a9 Thieme Medical Publishers; 2010. Treatment of ovarian hyperstimulation syndrome.", "ArticleIdList": ["21082512"]}, {"Citation": "Abou-Taleb A., Abdel-Rhman A., Samy E., Tawfeek H. Formulation and stability of rofecoxib suppositories. J. Drug Deliv. Sci. Technol. 2006;16(5):389\u2013396."}, {"Citation": "Alvarez C., et al. Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum. Reprod. 2007;22(12):3210\u20133214.", "ArticleIdList": ["17921134"]}, {"Citation": "\u00c1lvarez C., et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J. Clin. Endocrinol. Metab. 2007;92(8):2931\u20132937.", "ArticleIdList": ["17456571"]}, {"Citation": "Amir H., et al. Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. J. Reprod. Med. 2015;60(1\u20132):48\u201354.", "ArticleIdList": ["25745751"]}, {"Citation": "Ata, B., A. Seyhan, S. Orhaner, and B. Urman, High dose cabergoline in management of ovarian hyperstimulation syndrome. Fertility and sterility, 2009. 92(3): p. 1168. e1-1168. e4.", "ArticleIdList": ["19539908"]}, {"Citation": "Baeza Pertegaz I., Goikolea Alberdi J.M., Parellada Rodon E. Is cabergoline a better drug to inhibit lactation in patients with psychotic symptoms? J. Psychiatry Neurosci. 2002;27(1):54.", "ArticleIdList": ["PMC149796", "11836977"]}, {"Citation": "Baviskar, P., S. Jaiswal, S. Sadique, and A. Landged, Formulation and evaluation of lornoxicam suppositories. The Pharma Innovation, 2013. 2(7, Part A): p. 20."}, {"Citation": "Becica J., Dobereiner G.E. The roles of Lewis acidic additives in organotransition metal catalysis. Org. Biomol. Chem. 2019;17(8):2055\u20132069.", "ArticleIdList": ["30667450"]}, {"Citation": "Benet L.Z., Broccatelli F., Oprea T.I. BDDCS applied to over 900 drugs. AAPS J. 2011;13(4):519\u2013547.", "ArticleIdList": ["PMC3231854", "21818695"]}, {"Citation": "bharathi Balakrishnan, S., G.B. Veerakanellore, and T. Stalin, In-vitro dissolution rate and molecular docking studies of cabergoline drug with \u03b2-cyclodextrin. Journal of molecular structure, 2018. 1160: p. 1-8."}, {"Citation": "Carizza C., et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod. Biomed. Online. 2008;17(6):751\u2013755.", "ArticleIdList": ["19079957"]}, {"Citation": "Chen C.-D., et al. Update on management of ovarian hyperstimulation syndrome. Taiwanese J. Obstet. Gynecol. 2011;50(1):2\u201310.", "ArticleIdList": ["21482366"]}, {"Citation": "Christ A.P., et al. Development of doxycycline hyclate suppositories and pharmacokinetic study in rabbits. Eur. J. Pharm. Sci. 2020;142", "ArticleIdList": ["31706017"]}, {"Citation": "Colao A., Lombardi G., Annunziato L. Cabergoline. Expert Opin. Pharmacother. 2000;1(3):555\u2013574.", "ArticleIdList": ["11249538"]}, {"Citation": "Cristina C., et al. Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice. Endocrinology. 2005;146(7):2952\u20132962.", "ArticleIdList": ["15817666"]}, {"Citation": "Dash S., Murthy P.N., Nath L., Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol. Pharma. 2010;67(3):217\u2013223.", "ArticleIdList": ["20524422"]}, {"Citation": "Del Dotto P., Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin. Pharmacokinet. 2003;42:633\u2013645.", "ArticleIdList": ["12844325"]}, {"Citation": "Donders G. Diagnosis and management of bacterial vaginosis and other types of abnormal vaginal bacterial flora: a review. Obstet. Gynecol. Survey. 2010;65(7):462\u2013473.", "ArticleIdList": ["20723268"]}, {"Citation": "Eguchi K., et al. In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors. Endocr. J. 1995;42(2):153\u2013161.", "ArticleIdList": ["7627259"]}, {"Citation": "ABOU FAZELI, R., et al., Fonnulation, preparation and physico-chemical control of vaginal suppositories containing volatile oils of allium sativum and zataria multiflora. 2000."}, {"Citation": "Ferrero H., et al. Dopamine agonist inhibits vascular endothelial growth factor protein production and secretion in granulosa cells. Reprod. Biol. Endocrinol. 2015;13:1\u20135.", "ArticleIdList": ["PMC4574352", "26377185"]}, {"Citation": "Ferrero H., et al. Dopamine agonist inhibits vascular endothelial growth factor protein production and secretion in granulosa cells. Reprod. Biol. Endocrinol. 2015;13(1):104.", "ArticleIdList": ["PMC4574352", "26377185"]}, {"Citation": "Havaldar V.D., et al. Screening of suppository bases for rectal delivery of carbamazepine. Res. J. Pharm. Technol. 2017;10(8):2697\u20132703."}, {"Citation": "Johal H.S., Garg T., Rath G., Goyal A.K. Advanced topical drug delivery system for the management of vaginal candidiasis. Drug Deliv. 2016;23(2):550\u2013563.", "ArticleIdList": ["24959937"]}, {"Citation": "Kauss T., et al. Pharmaceutical development and optimization of azithromycin suppository for paediatric use. Int. J. Pharm. 2013;441(1\u20132):218\u2013226.", "ArticleIdList": ["PMC3605574", "23220079"]}, {"Citation": "Kilic N., et al. Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoingin vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna J. Med. 2015;5(04):123\u2013127.", "ArticleIdList": ["PMC4637949", "26629467"]}, {"Citation": "K\u0131l\u0131\u00e7 N., et al. Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna J. Med. 2015;5(4):123.", "ArticleIdList": ["PMC4637949", "26629467"]}, {"Citation": "Kumar L., et al. Preparation and characterisation of fluconazole vaginal films for the treatment of vaginal candidiasis. Indian J. Pharm. Sci. 2013;75(5):585.", "ArticleIdList": ["PMC3877521", "24403660"]}, {"Citation": "Leese G., Jeffreys R., Vora J. Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone. Postgrad. Med. J. 1997;73(862):507\u2013508.", "ArticleIdList": ["PMC2431370", "9307745"]}, {"Citation": "Leitao V.M., et al. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. Fertil. Steril. 2014;101(3):664\u2013675 e7.", "ArticleIdList": ["24360566"]}, {"Citation": "Mancini, T., F.F. Casanueva, and A. Giustina, Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am, 2008. 37(1): p. 67-99, viii.", "ArticleIdList": ["18226731"]}, {"Citation": "Miyagi M., et al. Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats. Biol. Pharm. Bull. 1996;19(9):1210\u20131213.", "ArticleIdList": ["8889042"]}, {"Citation": "Moradkhannejhad L., et al. Electrospinning of zein/propolis nanofibers; antimicrobial properties and morphology investigation. J. Mater. Sci. - Mater. Med. 2018;29(11):165.", "ArticleIdList": ["30392146"]}, {"Citation": "Motta T., et al. Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics. Fertil. Steril. 1996;65(2):440\u2013442.", "ArticleIdList": ["8566276"]}, {"Citation": "Njoku J.O., Mukherjee D., Webster G.K., L\u00f6benberg R. Amorphous solid dispersions in early stage of formulation development: predicting excipient influence on dissolution profiles using DDDPlus. Cellul. 2020;586(67.87):19.0."}, {"Citation": "Papaleo E., et al. Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. Hum. Reprod. 2001;16(11):2263\u20132266.", "ArticleIdList": ["11679501"]}, {"Citation": "Papanikolaou E.G., et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil. Steril. 2006;85(1):112\u2013120.", "ArticleIdList": ["16412740"]}, {"Citation": "Parmar K.R., Shah S.R., Sheth N.R. Studies in dissolution enhancement of ezetimibe by solid dispersions in combination with a surface adsorbent. Dissolut. Technol. 2011;8(3):55\u201361."}, {"Citation": "Perkampus, H.H., LJ Bellamy: The Infrared Spectra of Complex Molecules, Vol. 1, 3. Auflage, Chapman and Hall Ltd., London 1975, 433 Seiten, 32 Abb., 22 Tabellen, Preis:\u00a3 8.\u2014. 1976, Wiley Online Library."}, {"Citation": "Pivonello R., et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J. Clin. Endocrinol. Metab. 2009;94(1):223\u2013230.", "ArticleIdList": ["18957500"]}, {"Citation": "Sah M., Saini T. Formulation development and release studies of indomethacin suppositories. Indian J. Pharm. Sci. 2008;70(4):498.", "ArticleIdList": ["PMC2792559", "20046779"]}, {"Citation": "Schiff P.L. Ergot and its alkaloids. Am. J. Pharm. Educ. 2006;70(5):98.", "ArticleIdList": ["PMC1637017", "17149427"]}, {"Citation": "Sharma G., Mishra A.K., Mishra P., Misra A. Intranasal cabergoline: pharmacokinetic and pharmacodynamic studies. AAPS PharmSciTech. 2009;10(4):1321\u20131330.", "ArticleIdList": ["PMC2799595", "19894122"]}, {"Citation": "Singh S.K., Sinha S.K., Shirsat M.K. Design, synthesis and evaluation of 4-Aminopyridine analogues as Cholinesterase inhibitors for management of Alzheimer\u2019s diseases. Indian J. Pharm. Educ. 2018;52(4):644\u2013654."}, {"Citation": "Sinha S., et al. Dopamine regulates phosphorylation of VEGF receptor 2 by engaging Src-homology-2-domain-containing protein tyrosine phosphatase 2. J. Cell Sci. 2009;122(18):3385\u20133392.", "ArticleIdList": ["PMC2736867", "19706677"]}, {"Citation": "Soares S.R., et al. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum. Reprod. Update. 2008;14(4):321\u2013333.", "ArticleIdList": ["18385260"]}, {"Citation": "Speroff L., Fritz M.A. lippincott Williams & wilkins; 2005. Clinical gynecologic endocrinology and infertility."}, {"Citation": "Sudke S.G. Design of curcumin suppositories for effective treatment of vaginal candidiasis using cow ghee as a suppository base. Asian J. Pharma. (AJP) 2017;11(04)"}, {"Citation": "Sweetman, S.C., Martindale: the complete drug reference. 2005.", "ArticleIdList": ["PMC1181301", "16052024"]}, {"Citation": "Tang H., et al. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst. Rev. 2012;2", "ArticleIdList": ["22336848"]}, {"Citation": "Tanphaichitr N., et al. Potential use of antimicrobial peptides as vaginal spermicides/microbicides. Pharmaceuticals. 2016;9(1):13.", "ArticleIdList": ["PMC4812377", "26978373"]}, {"Citation": "Toffle R.C. \u201c There they go again\u201d\u2013hCG and weight loss. W. V. Med. J. 2011;107(1):12\u201314.", "ArticleIdList": ["21322466"]}, {"Citation": "Vaz V.M., Jitta S.R., Verma R., Kumar L. Hesperetin loaded proposomal gel for topical antioxidant activity. J. Drug Delivery Sci. Technol. 2021;66"}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "8", "Day": "15"}, {"Year": "2023", "Month": "10", "Day": "26"}, {"Year": "2023", "Month": "11", "Day": "29", "Hour": "18", "Minute": "43"}, {"Year": "2023", "Month": "11", "Day": "29", "Hour": "18", "Minute": "42"}, {"Year": "2023", "Month": "11", "Day": "29", "Hour": "17", "Minute": "11"}, {"Year": "2023", "Month": "11", "Day": "4"}], "PublicationStatus": "ppublish", "ArticleIdList": ["38028218", "PMC10663909", "10.1016/j.jsps.2023.101849", "S1319-0164(23)00344-4"]}}], "PubmedBookArticle": []}